Characterization of a single reporter-gene potency assay for T-cell-dependent bispecific molecules-Reference-Cited by-同舟云学术

Characterization of a single reporter-gene potency assay for T-cell-dependent bispecific molecules

Published:2019-07-26 Issue:7 Volume:11 Page:1245-1253
ISSN:1942-0862
Container-title:mAbs
language:en
Short-container-title:mAbs

Author:

Lee Ho Young¹,Register Ames¹^ORCID,Shim Jeongsup¹^ORCID,Contreras Edward¹,Wu Qiang¹^ORCID,Jiang Guoying¹^ORCID

Affiliation:

1. Biological Technologies, Department of Analytical Development and Quality Control, Genentech, A member of the Roche group, South San Francisco, CA, USA

Publisher

Informa UK Limited

Subject

Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/19420862.2019.1640548

Reference46 articles.

1. The making of bispecific antibodies

2. Bispecific antibodies: a mechanistic review of the pipeline

3. Engineering therapeutic bispecific antibodies using CrossMab technology

4. Alternative molecular formats and therapeutic applications for bispecific antibodies

5. Antitumor Activity of a Novel Bispecific Antibody That Targets the ErbB2/ErbB3 Oncogenic Unit and Inhibits Heregulin-Induced Activation of ErbB3

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Comprehensive Exploration of Bioluminescence Systems, Mechanisms, and Advanced Assays for Versatile Applications;Biochemistry Research International;2024-02-05

2. End-to-end approach for the characterization and control of product-related impurities in T cell bispecific antibody preparations;International Journal of Pharmaceutics: X;2023-12

3. T cell–Dependent Bispecific Therapy Enhances Innate Immune Activation and Antibody-Mediated Killing;Cancer Immunology Research;2023-10-27

4. State-of-the-art and emerging trends in analytical approaches to pharmaceutical-product commercialization;Current Opinion in Biotechnology;2022-12

5. Development of a reporter gene method to measure the bioactivity of anti-CD38 × CD3 bispecific antibody;Antibody Therapeutics;2021-10